| Project/Area Number |
15K10446
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Orthopaedic surgery
|
|---|
| Research Institution | Okayama University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
藤原 俊義 岡山大学, 医歯薬学総合研究科, 教授 (00304303)
尾崎 敏文 岡山大学, 医歯薬学総合研究科, 教授 (40294459)
國定 俊之 岡山大学, 医歯薬学総合研究科, 准教授 (80346428)
藤原 智洋 岡山大学, 医歯薬学総合研究科, 助教 (80639211)
|
|---|
| Project Period (FY) |
2015-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2017: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2016: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2015: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
|
|---|
| Keywords | 腫瘍融解アデノウイルス / 骨・軟部肉腫 / 放射線治療 / 併用療法 |
|---|
| Outline of Final Research Achievements |
Despite major advances in the treatment of bone and soft tissue sarcoma, those patients often show the refractory to conventional treatment, leading to poor prognosis. Therefore, the enhancement of sensitivity to radiotherapy is needed to improve the clinical outcome of bone and soft tissue sarcoma patients. We recently revealed that a tumor-specific, replication-competent oncolytic adenovirus Telomelysin (OBP-301) kills human sarcoma cells. In this study, we investigated the combination effect of Telomelysin and radiotherapy against human bone and soft tissue sarcoma cells. Combination with Telomelysin and radiotherapy showed more profound antitumor effect compared to monotherapy in vitro and in vivo. These results suggest that combination with Telomelysin and radiotherapy provides a novel therapeutic strategy for bone and soft tissue sarcoma.
|
